
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with John Sims, MD. [LISTEN TIME: 17 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with John Sims, MD. [LISTEN TIME: 17 minutes]

The head of medical development for donanemab at Eli Lilly and Company explained how donanemab’s modified titration dosing regimen could reduce ARIA risk and improve clinical decision-making following the drug’s FDA label update. [WATCH TIME: 3 minutes]

The head of medical development for donanemab at Eli Lilly and Company provided insights on the structure of TRAILBLAZER-ALZ 6, a study comparing numerous different dosing regimens of donanemab. [WATCH TIME: 3 minutes]